It is vitally important to continue the fight to save young children, particularly adolescent girls, from hormonal treatments that may permanently alter their bodies, and surgeries that may lead to profound regret.

This conclusion by the prestigious British Medical Journal (BMJ) shows incredible weakness of the arguments that medical organizations in the United States have used in favor of so-called “gender affirming care.” Flawed evidence is being presented in testimonies in front of legislative bodies and in promulgating recommendations for treatments that clearly, according to Norwegian experts, has the potential for doing more harm than good.

One of the key leaders of the evidence-based gender medicine movement, Dr. Gordon Guyatt, points out that the Endocrine Society guidelines vastly overstate the evidence for treating adolescents with new onset “gender dysphoria.”

Stanley Goldfarb, MD is the former associate dean of curriculum at the University of Pennsylvania Perelman School of Medicine and chairman of Do No Harm.

Last fall, Do No Harm sued pharmaceutical giant Pfizer over its Breakthrough Fellowship Program, a highly prestigious and competitive program which illegally excluded White and Asian candidates from applying.

The program’s requirements explicitly stated that applicants must “meet the program’s goals of increasing the pipeline for Black/African American, Latino/Hispanic and Native Americans.” 

In short – Pfizer was picking winners and losers based on their skin color. 

After a federal judge dismissed the case, Do No Harm immediately appealed, and following that appeal Pfizer has quietly – without any public announcement or fanfare – updated the Breakthrough Fellowships’ criteria

The new FAQ states: “You are eligible to apply for the Breakthrough Fellowship Program regardless of whether you are of Black/African American, Latino/Hispanic, or Native American descent.” 

“Do No Harm is pleased that Pfizer recognizes its blatant racial discrimination is unlawful and immoral,” said Dr. Stanley Goldfarm, MD, chairman of Do No Harm. “It is important to recognize that this significant change was made only after Do No Harm’s lawsuit, and only because Pfizer knows its fellowship is in jeopardy on appeal.”

Despite Pfizer’s under the radar change of course, Do No Harm will proceed with its lawsuit to ensure that Pfizer does not continue or resume its racial discrimination that has no place in society.  

About Do No Harm
Do No Harm is a diverse group of physicians, healthcare professionals, medical students, patients, and policymakers united by an ethical mission: Protect healthcare from a radical, divisive, and discriminatory ideology. They believe in making healthcare better for all – not undermining it in pursuit of a political agenda. Learn more at www.donoharmmedicine.org.